Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 117

1.

NI-1: a novel canine mastocytoma model for studying drug resistance and IgER-dependent mast cell activation.

Hadzijusufovic E, Peter B, Herrmann H, Rülicke T, Cerny-Reiterer S, Schuch K, Kenner L, Thaiwong T, Yuzbasiyan-Gurkan V, Pickl WF, Willmann M, Valent P.

Allergy. 2012 Jul;67(7):858-68. doi: 10.1111/j.1398-9995.2012.02833.x.

2.

KIT polymorphisms and mutations determine responses of neoplastic mast cells to bafetinib (INNO-406).

Peter B, Hadzijusufovic E, Blatt K, Gleixner KV, Pickl WF, Thaiwong T, Yuzbasiyan-Gurkan V, Willmann M, Valent P.

Exp Hematol. 2010 Sep;38(9):782-91. doi: 10.1016/j.exphem.2010.05.004.

PMID:
20685234
3.

Synergistic antiproliferative effects of KIT tyrosine kinase inhibitors on neoplastic canine mast cells.

Gleixner KV, Rebuzzi L, Mayerhofer M, Gruze A, Hadzijusufovic E, Sonneck K, Vales A, Kneidinger M, Samorapoompichit P, Thaiwong T, Pickl WF, Yuzbasiyan-Gurkan V, Sillaber C, Willmann M, Valent P.

Exp Hematol. 2007 Oct;35(10):1510-21.

PMID:
17681669
4.

Identification of c-kit mutations-independent neoplastic cell proliferation of canine mast cells.

Ohmori K, Kawarai S, Yasuda N, Tanaka A, Matsuda H, Nishimura R, Sasaki N, Tsujimoto H, Masuda K.

Vet Immunol Immunopathol. 2008 Nov 15;126(1-2):43-53. doi: 10.1016/j.vetimm.2008.06.014.

PMID:
18687474
5.

Novel thiazole amine class tyrosine kinase inhibitors induce apoptosis in human mast cells expressing D816V KIT mutation.

Jin Y, Ding K, Wang D, Shen M, Pan J.

Cancer Lett. 2014 Oct 10;353(1):115-23. doi: 10.1016/j.canlet.2014.07.017.

PMID:
25088577
6.

In vitro and in vivo growth-inhibitory effects of cladribine on neoplastic mast cells exhibiting the imatinib-resistant KIT mutation D816V.

Böhm A, Sonneck K, Gleixner KV, Schuch K, Pickl WF, Blatt K, Peter B, Herrmann H, Schernthaner GH, Pehamberger H, Rabitsch W, Sperr WR, Valent P.

Exp Hematol. 2010 Sep;38(9):744-55. doi: 10.1016/j.exphem.2010.05.006.

PMID:
20553795
7.

H1-receptor antagonists terfenadine and loratadine inhibit spontaneous growth of neoplastic mast cells.

Hadzijusufovic E, Peter B, Gleixner KV, Schuch K, Pickl WF, Thaiwong T, Yuzbasiyan-Gurkan V, Mirkina I, Willmann M, Valent P.

Exp Hematol. 2010 Oct;38(10):896-907. doi: 10.1016/j.exphem.2010.05.008.

8.

The PI3-kinase/mTOR-targeting drug NVP-BEZ235 inhibits growth and IgE-dependent activation of human mast cells and basophils.

Blatt K, Herrmann H, Mirkina I, Hadzijusufovic E, Peter B, Strommer S, Hoermann G, Mayerhofer M, Hoetzenecker K, Klepetko W, Ghanim V, Marth K, Füreder T, Wacheck V, Valenta R, Valent P.

PLoS One. 2012;7(1):e29925. doi: 10.1371/journal.pone.0029925.

9.

EXEL-0862, a novel tyrosine kinase inhibitor, induces apoptosis in vitro and ex vivo in human mast cells expressing the KIT D816V mutation.

Pan J, Quintás-Cardama A, Kantarjian HM, Akin C, Manshouri T, Lamb P, Cortes JE, Tefferi A, Giles FJ, Verstovsek S.

Blood. 2007 Jan 1;109(1):315-22.

10.

The antitumor activity of homoharringtonine against human mast cells harboring the KIT D816V mutation.

Jin Y, Lu Z, Cao K, Zhu Y, Chen Q, Zhu F, Qian C, Pan J.

Mol Cancer Ther. 2010 Jan;9(1):211-23. doi: 10.1158/1535-7163.MCT-09-0468.

11.

Ponatinib induces apoptosis in imatinib-resistant human mast cells by dephosphorylating mutant D816V KIT and silencing β-catenin signaling.

Jin B, Ding K, Pan J.

Mol Cancer Ther. 2014 May;13(5):1217-30. doi: 10.1158/1535-7163.MCT-13-0397.

12.

Biological effect of tyrosine kinase inhibitors on three canine mast cell tumor cell lines with various KIT statuses.

Takeuchi Y, Fujino Y, Fukushima K, Watanabe M, Nakagawa T, Ohno K, Sasaki N, Sugano S, Tsujimoto H.

J Vet Pharmacol Ther. 2012 Feb;35(1):97-104. doi: 10.1111/j.1365-2885.2011.01296.x.

PMID:
21480930
13.

Ex vivo evaluation of imatinib mesylate for induction of cell death on canine neoplastic mast cells with mutations in c-Kit exon 11 via apoptosis.

Rossi G, Bertani C, Mari S, Marini C, Renzoni G, Ogilvie G, Magi GE.

Vet Res Commun. 2013 Jun;37(2):101-8. doi: 10.1007/s11259-013-9550-5.

PMID:
23315207
14.

Polo-like kinase-1 as a novel target in neoplastic mast cells: demonstration of growth-inhibitory effects of small interfering RNA and the Polo-like kinase-1 targeting drug BI 2536.

Peter B, Gleixner KV, Cerny-Reiterer S, Herrmann H, Winter V, Hadzijusufovic E, Ferenc V, Schuch K, Mirkina I, Horny HP, Pickl WF, Müllauer L, Willmann M, Valent P.

Haematologica. 2011 May;96(5):672-80. doi: 10.3324/haematol.2010.031328.

15.

Mast cell leukemia: identification of a new c-Kit mutation, dup(501-502), and response to masitinib, a c-Kit tyrosine kinase inhibitor.

Georgin-Lavialle S, Lhermitte L, Suarez F, Yang Y, Letard S, Hanssens K, Feger F, Renand A, Brouze C, Canioni D, Asnafi V, Chandesris MO, Aouba A, Gineste P, Macintyre E, Mansfield CD, Moussy A, Lepelletier Y, Dubreuil P, Hermine O.

Eur J Haematol. 2012 Jul;89(1):47-52. doi: 10.1111/j.1600-0609.2012.01761.x.

PMID:
22324351
16.

Transcriptome and proteome analysis of tyrosine kinase inhibitor treated canine mast cell tumour cells identifies potentially kit signaling-dependent genes.

Klopfleisch R, Meyer A, Schlieben P, Bondzio A, Weise C, Lenze D, Hummel M, Einspanier R, Gruber AD.

BMC Vet Res. 2012 Jun 29;8:96. doi: 10.1186/1746-6148-8-96.

17.

Growth-inhibitory effects of four tyrosine kinase inhibitors on neoplastic feline mast cells exhibiting a Kit exon 8 ITD mutation.

Hadzijusufovic E, Peter B, Rebuzzi L, Baumgartner C, Gleixner KV, Gruze A, Thaiwong T, Pickl WF, Yuzbasiyan-Gurkan V, Willmann M, Valent P.

Vet Immunol Immunopathol. 2009 Dec 15;132(2-4):243-50. doi: 10.1016/j.vetimm.2009.05.007.

PMID:
19505729
18.

Molecular changes associated with the development of resistance to imatinib in an imatinib-sensitive canine neoplastic mast cell line carrying a KIT c.1523A>T mutation.

Kobayashi M, Kuroki S, Tanaka Y, Moriya Y, Kozutumi Y, Uehara Y, Ono K, Tamura K, Washizu T, Bonkobara M.

Eur J Haematol. 2015 Dec;95(6):524-31. doi: 10.1111/ejh.12526.

PMID:
25684098
19.

A new human mast cell line expressing a functional IgE receptor converts to tumorigenic growth by KIT D816V transfection.

Saleh R, Wedeh G, Herrmann H, Bibi S, Cerny-Reiterer S, Sadovnik I, Blatt K, Hadzijusufovic E, Jeanningros S, Blanc C, Legarff-Tavernier M, Chapiro E, Nguyen-Khac F, Subra F, Bonnemye P, Dubreuil P, Desplat V, Merle-Béral H, Willmann M, Rülicke T, Valent P, Arock M.

Blood. 2014 Jul 3;124(1):111-20. doi: 10.1182/blood-2013-10-534685.

20.

The novel HSP90 inhibitor STA-9090 exhibits activity against Kit-dependent and -independent malignant mast cell tumors.

Lin TY, Bear M, Du Z, Foley KP, Ying W, Barsoum J, London C.

Exp Hematol. 2008 Oct;36(10):1266-77. doi: 10.1016/j.exphem.2008.05.001.

Supplemental Content

Support Center